Avara Pharmaceutical Services

Belkins
Home Avara Pharmaceutical Services is a state of the art Contract Manufacturing Organization. We focus our efforts on Quality, Compliance, Customer Service, and delivering on time and in-full. We have a senior leadership that have managed manufacturing infrastructures worldwide. Avara Pharmaceutical Services was founded by a team of industry veterans who, through personal experience, understand both sides of the contract manufacturing market. Our team is fully aware of customers’ expectations. Therefore, we built a CDMO that provides exceptional service and a world-class experience by delivering on our commitments. These commitments include delivering to scope, schedule, meeting regulatory requirements and quality standards, all at an agreed and fair price.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

GILEAD GETS WHO COLD SHOULDER FOR REMDESIVIR IN COVID-19, LAUNCHES SPEEDY DEFENSE

Gilead | November 21, 2020

news image

Gilead Sciences’ Veklury, better known as remdesivir, is so far the only COVID-19 therapy officially approved by the FDA, but the World Health Organization has some other ideas about the drug’s worth. At clear odds with the FDA’s approval, the WHO has for now recommended against the use of remdesivir in any hospitalized patients—regardless of disease severity—after an expert panel said it had found no evidence that remdesivir has any meaningful effect...

Read More

OPEN ORPHAN SECURES STUDY TRIAL CONTRACT WITH MYSTERY PHARMACEUTICAL COMPANY

Open Orphan | August 10, 2020

news image

Pharmaceutical services company Open Orphan has scored a £4.0m contract with an unnamed top-three global pharmaceutical company to be the sponsor of and provide a respiratory syncytial virus human challenge study trial. Open Orphan said the new contract represented the continued conversion of its substantial pipeline and generation of significant cash flow. The AIM-listed group added that the study would take place in subsidiary hVIVO's London-based quarantine unit and was expected to ...

Read More

LEVINE LEICHTMAN CAPITAL PARTNERS PORTFOLIO COMPANY CAPSA HEALTHCARE ACQUIRES ROBOPHARMA

Capsa Healthcare | August 14, 2020

news image

Capsa Healthcare ("Capsa"), a portfolio company of Levine Leichtman Capital Partners ("LLCP"), announced today that it has acquired NewRobo Development B.V. and subsidiaries (collectively, "RoboPharma"). RoboPharma, based in Waalwijk, Netherlands, creates and implements pharmacy automation solutions for some of the largest pharmacies in Europe. Capsa is a leading provider of innovative, highly engineered workflow products that increase efficiency and reduce costs, e...

Read More

BUSINESS INSIGHTS

VIRPAX PHARMACEUTICALS ENGAGES TORREYA CAPITAL TO ADVISE ON GLOBAL PARTNERING EFFORTS

Torreya Capital, Virpax Pharmaceuticals | April 23, 2021

news image

Virpax® Pharmaceuticals, Inc. reported today that it has appointed Torreya Capital, LLC as the Company's sole financial adviser for its partnering and licensing activities in strategic global markets. Torreya is a leading investment bank that has supported more than $100 billion in life sciences transactions since its establishment in 2007. “We are thrilled to be collaborating with Torreya to extend our partnerships in key markets,” said Anthony ...

Read More

RESEARCH

Gilead | November 21, 2020

news image

GILEAD GETS WHO COLD SHOULDER FOR REMDESIVIR IN COVID-19, LAUNCHES SPEEDY DEFENSE

Gilead Sciences’ Veklury, better known as remdesivir, is so far the only COVID-19 therapy officially approved by the FDA, but the World Health Organization has some other ideas about the drug’s worth. At clear odds with the FDA’s approval, the WHO has for now recommended against the use of remdesivir in any hospitalized patients—regardless of disease severity—after an expert panel said it had found no evidence that remdesivir has any meaningful effect...

Read More

Open Orphan | August 10, 2020

news image

OPEN ORPHAN SECURES STUDY TRIAL CONTRACT WITH MYSTERY PHARMACEUTICAL COMPANY

Pharmaceutical services company Open Orphan has scored a £4.0m contract with an unnamed top-three global pharmaceutical company to be the sponsor of and provide a respiratory syncytial virus human challenge study trial. Open Orphan said the new contract represented the continued conversion of its substantial pipeline and generation of significant cash flow. The AIM-listed group added that the study would take place in subsidiary hVIVO's London-based quarantine unit and was expected to ...

Read More

Capsa Healthcare | August 14, 2020

news image

LEVINE LEICHTMAN CAPITAL PARTNERS PORTFOLIO COMPANY CAPSA HEALTHCARE ACQUIRES ROBOPHARMA

Capsa Healthcare ("Capsa"), a portfolio company of Levine Leichtman Capital Partners ("LLCP"), announced today that it has acquired NewRobo Development B.V. and subsidiaries (collectively, "RoboPharma"). RoboPharma, based in Waalwijk, Netherlands, creates and implements pharmacy automation solutions for some of the largest pharmacies in Europe. Capsa is a leading provider of innovative, highly engineered workflow products that increase efficiency and reduce costs, e...

Read More

BUSINESS INSIGHTS

Torreya Capital, Virpax Pharmaceuticals | April 23, 2021

news image

VIRPAX PHARMACEUTICALS ENGAGES TORREYA CAPITAL TO ADVISE ON GLOBAL PARTNERING EFFORTS

Virpax® Pharmaceuticals, Inc. reported today that it has appointed Torreya Capital, LLC as the Company's sole financial adviser for its partnering and licensing activities in strategic global markets. Torreya is a leading investment bank that has supported more than $100 billion in life sciences transactions since its establishment in 2007. “We are thrilled to be collaborating with Torreya to extend our partnerships in key markets,” said Anthony ...

Read More